Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies. - sprookjes - yvandenbroek - TriplyDB

Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies.

Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies.

http://www.wikidata.org/entity/Q37629584

about

A novel monoclonal anti-CD81 antibody produced by genetic immunization efficiently inhibits Hepatitis C virus cell-cell transmission Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents A Hepatitis C Virus Envelope Polymorphism Confers Resistance to Neutralization by Polyclonal Sera and Broadly Neutralizing Monoclonal Antibodies Hepatitis C virus cell entry: a target for novel antiviral strategies to address limitations of direct acting antivirals.Neutralizing antibodies in patients with chronic hepatitis C, genotype 1, against a panel of genotype 1 culture viruses: lack of correlation to treatment outcome.Genotype 1 hepatitis C virus envelope features that determine antiviral response assessed through optimal covariance networks.Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C.Syndecan 4 is involved in mediating HCV entry through interaction with lipoviral particle-associated apolipoprotein E Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance.Neutralization resistance of hepatitis C virus can be overcome by recombinant human monoclonal antibodies Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody Tannic Acid Inhibits Hepatitis C Virus Entry into Huh7.5 Cells Applying antibody-sensitive hypervariable region 1-deleted hepatitis C virus to the study of escape pathways of neutralizing human monoclonal antibody AR5A.Extra-epitopic hepatitis C virus polymorphisms confer resistance to broadly neutralizing antibodies by modulating binding to scavenger receptor B1 Neutralizing antibodies and pathogenesis of hepatitis C virus infection.Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study.Novel mutations in Marburg virus glycoprotein associated with viral evasion from antibody mediated immune pressure.Hepatitis C virus, cholesterol and lipoproteins--impact for the viral life cycle and pathogenesis of liver disease.New perspectives for preventing hepatitis C virus liver graft infection.Exosome-mediated transmission of hepatitis C virus between human hepatoma Huh7.5 cells.Sequence and functional analysis of the envelope glycoproteins of hepatitis C virus variants selectively transmitted to a new host.Global mapping of antibody recognition of the hepatitis C virus E2 glycoprotein: Implications for vaccine design.HVR1-mediated antibody evasion of highly infectious in vivo adapted HCV in humanised mice.CD81-receptor associations--impact for hepatitis C virus entry and antiviral therapies.Synthetic anti-lipopolysaccharide peptides and hepatitis C virus infection.Viral (hepatitis C virus, hepatitis B virus, HIV) persistence and immune homeostasis.Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies.Viral evasion and challenges of hepatitis C virus vaccine development.The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination.Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection.Broad neutralization of hepatitis C virus-resistant variants by Civacir hepatitis C immunoglobulin.A cinnamon-derived procyanidin type A compound inhibits hepatitis C virus cell entry.Monoclonal anti-envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus challenge.Tracking HCV protease population diversity during transmission and susceptibility of founder populations to antiviral therapy.Hepatitis C virus resistance to broadly neutralizing antibodies measured using replication-competent virus and pseudoparticles.CD81 sequence and susceptibility to hepatitis C infection.Hepatitis C virus envelope glycoprotein signatures are associated with treatment failure and modulation of viral entry and neutralization.A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo.A protein coevolution method uncovers critical features of the Hepatitis C Virus fusion mechanism.Mapping Determinants of Virus Neutralization and Viral Escape for Rational Design of a Hepatitis C Virus Vaccine.

P2860

Q28488372-6ECCD575-40E6-4367-AFF2-CC2476886D97 Q28538891-BC48C376-71A1-448D-8BB3-38F431E17D93 Q30383939-22D35BED-E47C-48ED-8E48-912DCAFADB57 Q30386551-3E29DB76-5566-454C-A05B-0C2DB5BDE28D Q34717544-147DFB99-81DB-4F78-B1CA-6679A50C0DAE Q34806845-E077D52F-1E4C-4A08-95D8-767900873B0E Q35135565-2E642733-2019-4FAC-84EC-E5FE89EE2A87 Q35153978-AF8E60B1-1D57-43DD-9E39-3037E06FDC9E Q35242585-F0E6CBE7-97FD-45AF-8CF9-F709650AED0F Q35557495-31B3B0A4-9B78-4237-BF03-C26B09A93608 Q35602284-44AEA88C-9C1E-4E91-8065-E6B88E1E80D2 Q35695028-FC7F184B-FE9B-4C81-B61E-607A7C1CDDCA Q36288404-B543354F-AF5F-4505-AD19-537F7657F3C3 Q36290295-83BF4FBB-5B58-413C-BB6F-C30C54CA1998 Q36395837-D1C7A153-58DB-41EF-8C98-03340BCD5874 Q36745425-B16B1EE8-AAAD-47D2-9A41-63CEB2168E2D Q37007013-7303B095-74EE-4897-81DE-D92DD8E9801A Q37015738-B8F8258B-0688-4994-ACF6-B422E9B9B640 Q37015805-6AC52155-2279-4115-8149-FDC1BBABA25F Q37088676-90545F9A-BCA3-4775-9773-D5D63D205D56 Q37336742-89A3BB07-C300-4B24-BBA4-7C36461F0CF7 Q37417999-573FBA93-DED6-4DA4-AAE3-8F0232F75F3D Q37471718-EA0140E2-5221-48A9-9674-36D60CA9A857 Q37611842-C0FEE3F9-419D-4A26-914F-32D001BFD12D Q38103293-2CD4BADE-1107-45DD-992E-A6CDE1696E2A Q38223279-008942F7-A4E5-4AB2-8F17-7C51002FFEE8 Q38856649-62C64A49-8F5B-4BFE-B319-FD1E604D7ADF Q38961608-EAF9CEF0-EB31-42DF-B31D-EDD68C229F88 Q39256583-E6A11134-0AEF-4C29-A58B-C1E7412A7BFB Q39403799-51C5CB66-D94E-42A2-8101-8C5465188DA5 Q39483891-27E0B9EC-5F16-47A1-BAFB-4B1A837CABEC Q40126459-39D2B40E-2646-4684-B8C9-69FA7045091F Q40165519-234E69B0-7E78-494A-88CA-7B8211C0C83C Q40382054-3869F51A-1C81-4386-AB12-4D746437AEC8 Q40527984-FC94AA2E-EA3B-4BF0-948A-F84A464918A2 Q42262704-D311B06E-25C1-4488-BB29-40667BFEC40E Q42988476-4B2E8D6F-17DA-4448-9887-782B3568ED27 Q45325612-B04D6691-E182-420C-8FC2-8BDC0A1408B2 Q51149647-B1F62FD0-4740-4198-9BC4-FED95035DA9F Q55282191-FD03A492-AEB8-4A53-9CE8-8FBB07931771

P2860

Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies.

http://www.wikidata.org/entity/Q37629584

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 10 April 2012

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Mutations that alter use of he ...... from neutralizing antibodies.

@en

Mutations that alter use of he ...... from neutralizing antibodies.

@nl

type

label

Mutations that alter use of he ...... from neutralizing antibodies.

@en

Mutations that alter use of he ...... from neutralizing antibodies.

@nl

prefLabel

Mutations that alter use of he ...... from neutralizing antibodies.

@en

Mutations that alter use of he ...... from neutralizing antibodies.

@nl

P1433

Q37629584-C9FB4328-26A6-434E-9353-EE067EF99A58

P1476

Q37629584-033D6882-AEF2-4E08-853C-7503E54DF393

P2093

Q37629584-008A14A4-5AF1-4494-A197-4046F95CE990

Q37629584-037580EF-F317-4058-A336-CB2423477ED0

Q37629584-0924632B-B2F9-4DCB-B8A3-0D751B277238

Q37629584-348E8367-697B-4A5A-AD84-121C8166FBC2

Q37629584-3B0F6E63-064D-41D7-841F-BA9CA8129B00

Q37629584-4E622F5C-9449-4ACF-95E1-9DF1E2D6798C

Q37629584-604B5F59-85F7-47CE-866B-6863DD3E4B9D

Q37629584-6C164387-BFCF-4FDB-ABB1-A91413E4E6F8

Q37629584-79E1FD10-A7D2-4B02-A286-5A72161EAA1B

Q37629584-87BB4CFE-9516-47CB-9803-D69B30CE53E4

P2860

Q37629584-0164707F-B720-491A-B63B-77E5E9DD3DDB

Q37629584-0442A141-2F58-490D-B936-765BB8390CEB

Q37629584-0E61E82D-FE14-494A-A97F-78ACD1C2DFD8

Q37629584-1607AE6E-FF60-42EB-9F3E-074C41FBE3BC

Q37629584-24E6DA30-12EC-495F-986B-6689D106215A

Q37629584-2BE9D9A0-42D4-4071-AC64-E5999DC0A7FD

Q37629584-2F2DC41A-D5D5-46A3-AB19-03CD3C7B410C

Q37629584-3B689529-390C-4939-B8D4-0077978F701E

Q37629584-3B85203B-CE30-4468-B4E0-DF58A9A33349

Q37629584-3C020229-D980-4C91-B4A8-567BA281830A

P304

Q37629584-3555AF6D-678B-4CDF-9B37-BBC6C6E55213

P31

Q37629584-E7A07AF8-9F31-4317-A72F-542F1F9C49AD

P356

Q37629584-9EC783AD-607D-4FA2-BB92-932FF77C2491

P407

Q37629584-1CA15F1B-DF82-439C-95C5-C36A8524CDAE

P433

Q37629584-D36CEC85-7121-4936-8745-E02DF4B7B7D5

P478

Q37629584-BDF50384-06AF-4A47-BCB5-98CC34878988

P50

Q37629584-0A1F2CBA-B489-4AEF-A825-091B3BAD7B11

Q37629584-FA689D85-3CE1-41A4-B53F-C6CF7DE4DA5B

P577

Q37629584-A685F79D-11C4-4AA0-AC13-AFE9BBC2A009

P5875

Q37629584-6BEF1AAA-1DAB-41E9-831F-937EF64A7C9F

P698

Q37629584-9A38B322-0A5D-4DC0-B0DE-134228C5A7A9

P921

Q37629584-71BBEF6D-F481-4B97-9232-D354C31E31AF

P932

Q37629584-C087493D-095B-47D8-8377-22D8C2CAD0DF

P356

J.GASTRO.2012.04.006

P1433

Gastroenterology

P1476

Mutations that alter use of he ...... from neutralizing antibodies.

@en

P2093

Catherine Fauvelle

http://www.w3.org/2001/XMLSchema#string

Christophe Combet

http://www.w3.org/2001/XMLSchema#string

François Habersetzer

http://www.w3.org/2001/XMLSchema#string

Françoise Stoll-Keller

http://www.w3.org/2001/XMLSchema#string

Isabel Fofana

http://www.w3.org/2001/XMLSchema#string

Juliette Hayer

http://www.w3.org/2001/XMLSchema#string

Karine Cury

http://www.w3.org/2001/XMLSchema#string

Laura Heydmann

http://www.w3.org/2001/XMLSchema#string

Marie-Sophie Hiet

http://www.w3.org/2001/XMLSchema#string

Marine Turek

http://www.w3.org/2001/XMLSchema#string

P2860

Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes

Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection

Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes

Monoclonal Antibody AP33 Defines a Broadly Neutralizing Epitope on the Hepatitis C Virus E2 Envelope Glycoprotein

Characterization of the Early Steps of Hepatitis C Virus Infection by Using Luciferase Reporter Viruses

A Conserved Gly436-Trp-Leu-Ala-Gly-Leu-Phe-Tyr Motif in Hepatitis C Virus Glycoprotein E2 Is a Determinant of CD81 Binding and Viral Entry

Identification of Conserved Residues in the E2 Envelope Glycoprotein of the Hepatitis C Virus That Are Critical for CD81 Binding

The Level of CD81 Cell Surface Expression Is a Key Determinant for Productive Entry of Hepatitis C Virus into Host Cells

Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C

The Neutralizing Activity of Anti-Hepatitis C Virus Antibodies Is Modulated by Specific Glycans on the E2 Envelope Protein

P304

223-233.e9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/J.GASTRO.2012.04.006

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

143

http://www.w3.org/2001/XMLSchema#string

P50

Ralf Bartenschlager

François-Loïc Cosset

P577

2012-04-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224037587

http://www.w3.org/2001/XMLSchema#string

P698

22503792

http://www.w3.org/2001/XMLSchema#string

P921

P932

5295797

http://www.w3.org/2001/XMLSchema#string